Author: therawinformant

  • Would Warren Buffett buy a2 Milk Company shares?

    warren buffett

    warren buffettwarren buffett

    One of the most successful investors in history is Berkshire Hathaway’s Warren Buffett.

    At the last count the legendary investor had amassed a fortune of US$77.4 billion according to Forbes.

    In order to get there, the “Oracle of Omaha” has invested wisely and with a long-term view.

    While amassing a similar fortune may be difficult, I believe regular investors can still create significant wealth by following his investing principles.

    Four key principles that Buffett follows are listed below. I’ve used these principles to see if A2 Milk Company Ltd (ASX: A2M) would be a share that he would invest in. Here’s what I found:

    Buffett invests in companies that he can understand.

    The a2 Milk Company is a premium branded fresh milk and infant nutrition company that is uniquely focused on products containing the a2 beta-casein protein type. Dairy products with just the a2 protein are believed to be easier to consume for those who experience challenges drinking conventional cows’ milk, which includes both a1 and a2 proteins. I think it is a very simple business to understand with clear drivers of demand. As a result, I think it gets a tick for this principle.

    Buffett looks for companies with a durable competitive advantage.

    Although the popularity of a2 Milk Company’s products has led to other dairy companies launching their own a2-only products, this hasn’t diminished demand from consumers. In fact, many believe that this has only strengthened its brand in the eyes of Chinese consumers. This is because the launch of a2 only products by big multinationals reinforces the a2 Milk Company’s premium brand in this key market. In light of this, I think its competitive advantage is here to stay.

    Management must be talented and have integrity.

    There has been a bit of upheaval at the company over the last 12 months, with former CEO Jayne Hrdlicka believed to have been forced out in December. Ms Hrdlicka “agreed to step down” from her role with immediate effect and was replaced with former CEO, Geoffrey Babidge. He replaced Hrdlicka on an interim basis while the board searches globally for a permanent replacement. While we don’t know who the next leader of a2 Milk Company will be, I’m confident it has the power to attract a high calibre executive to take it to the next level.

    Don’t overpay for shares.

    At present a2 Milk Company’s shares are changing hands at 34x estimated FY 2021. While this is not conventionally cheap, I feel its outlook justifies this premium. I believe a2 Milk Company has the potential to grow its earnings at an above-average rate for a number of years to come. This is thanks to the growing popularity of its infant formula in China, its modest market share in the lucrative market, and its expanding fresh milk footprint. Another positive is its hefty cash balance. I suspect this could be deployed for earnings accretive acquisitions in the near future.

    Conclusion.

    While Buffett may prefer to buy a2 Milk Company at a cheaper price, overall I think it is a share that he would approve of. I would class it as a strong buy for investors that are interested in making a long term investment.

    These 3 stocks could be the next big movers in 2020

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

    *Returns as of 6/8/2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Would Warren Buffett buy a2 Milk Company shares? appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2XHkzGa

  • Why ResMed shares could be a fantastic buy and hold option

    The ResMed. Inc (ASX: RMD) share price was the worst performer on the ASX 200 last week.

    The medical device company’s shares fell 11.4% over the period in response to the release of its full year results.

    Is this a buying opportunity?

    I think the pullback in the ResMed share price has created a buying opportunity for investors. Especially for those that are planning to make a long term investment, as I believe it has a very bright future ahead of it.

    This is because ResMed has a focus on the lucrative sleep treatment and ventilator markets. It designs, develops, and manufactures masks to treat sleep disorders such as sleep apnoea. It also has a growing software business which provides solutions that support sufferers of sleep disorders.

    On its investor call last week, management noted that there are 936 million people with sleep apnoea globally. There are also over 380 million people who suffer from chronic obstructive pulmonary disease (COPD) and over 340 million people living with asthma.

    This gives it a massive addressable market to grow into over the next decade. So much so, management is aiming to improve a total of 250 million lives by 2025. This compares to the 16 million lives it improved in FY 2020 by providing them with a device or complete mask system to help them breathe.

    Growing software business and R&D.

    Another key attraction to the company for me is its software business. Management believes this business is a competitive advantage and it is hard to disagree.

    At the end of FY 2020, ResMed’s digital health ecosystem had grown to over 12 million cloud connectable medical devices, with around 14 million patients enrolled in the AirView software solution. There are numerous benefits to this growing ecosystem, including recurring revenues and high levels of quality data. It is using this data to perform sophisticated analytics and drive actionable insights.

    Pleasingly, management isn’t resting on its laurels and continues to invest heavily in research and development in an effort to cement its leadership position in the industry. It spent US$202 million on these activities in FY 2020 and intends to grow its investment in the double digits in FY 2021.

    It notes that it has a full pipeline of innovative solutions that will generate both medium and long-term growth opportunities. It also has an industry-leading intellectual property portfolio of over 6,000 patents and designs.

    Foolish Takeaway.

    Given its strong position in the industry, its massive market opportunity, and its investments in research and development, I believe ResMed remains one of the best buy and hold options on the Australian share market.

    These 3 stocks could be the next big movers in 2020

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

    *Returns as of 6/8/2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why ResMed shares could be a fantastic buy and hold option appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3a95Cl5

  • 10 Stocks to Buy for Your 10-Year-Old

    10 Stocks to Buy for Your 10-Year-OldEditor's note: "10 Stocks to Buy for Your 10-Year-Old" was previously published in April 2020. It has since been updated to include the most relevant information available.With the markets still shakey from the novel coronavirus, it's very difficult to predict the day-to-day movements. On the other hand, figuring out which stocks to buy for your ten-year-old is a much easier task. That comes from the confidence that over time, many well-positioned companies will benefit from shifting social dynamics.Overall, the biggest change that we'll see is the continued rise and proliferation of digitalization. Of course, we see this impact through e-commerce, which has steadily taken share of total retail sales in the U.S. Just as importantly, digitalization has transformed the way we work via innovations such as cloud computing.InvestorPlace – Stock Market News, Stock Advice & Trading TipsWithin the technology realm, I forecast several stocks to buy running higher on the gig economy. The concept of the tethered, nine-to-five schedule is gradually losing relevance. Increasingly, work-life balance ranks highly among young professionals. Plus, with the aforementioned innovation of cloud computing, telecommuting is now easier and more sensible than ever. * 7 Travel Stocks to Buy Banking On Pent-Up Demand On a related note, advancements in tech should allow more people to participate in the digitalized economy. Thanks to incredible progress in mobile payment processors, small companies are able to compete with larger rivals. Therefore, stocks to buy which feature underlining businesses that harness the power of the information age will likely jump higher.Despite drastic changes, some things will always stay the same. As the coronavirus proves, people will still get sick. And no matter what, people require downtime to refocus and re-energize. Here are the 10 stocks to buy for your ten-year-old. * Amazon (NASDAQ:AMZN) * Uber Technologies (NYSE:UBER) * Fiverr International (NYSE:FVRR) * Square (NYSE:SQ) * PayPal (NASDAQ:PYPL) * H&R Block (NYSE:HRB) * Splunk (NASDAQ:SPLK) * American Outdoor Brands (NASDAQ:AOBC) * Teva Pharmaceutical (NYSE:TEVA) * Disney (NYSE:DIS)In this article, I've tried to create an eclectic list of companies that should be relevant over the next decade or so. Stocks to Buy for Your 10-Year-Old: Amazon (AMZN)Source: Jonathan Weiss / Shutterstock.com After screaming to all-time highs, the coronavirus outbreak took the wind out of e-commerce giant Amazon's sails — for a while. It has already sharply rebounded off its coronavirus lows. And I'm confident in AMZN stock longer term.No health crisis can overcome the power of human ingenuity, which is what Amazon is.In the fourth quarter of 2019, e-commerce represented 11.4% of total retail sales in the U.S. I'm not entirely sure what this allocation will be in 2030. Suffice to say, though, that it will be substantially higher. Like Alphabet's (NASDAQ:GOOG, NASDAQ:GOOGL) Google, Amazon has become part of the social lexicon. That bodes very well for Amazon stock.Another reason to keep this behemoth on your list of stocks to buy is that Amazon is disrupting everything it can. From the cloud to healthcare to groceries, Amazon's footprint is everywhere. Sure, that ruffles some folks' feathers. But if you can't beat 'em — and no, you can't beat Amazon — you might as well buy their stock. Uber Technologies (UBER)Source: NYCStock / Shutterstock.com For one reason or another, Uber manages to find itself in the news frequently. Of course, some of it is not for particularly great reasons.For one, many have blasted the company for harboring an aggressive and toxic work culture. And its relationship with its drivers is not always mutually agreeable. Nevertheless, UBER stock is a name to keep in mind over the long haul.Primarily, the company has managed to upend the taxi industry. Frankly, it's about time someone did. Taxis are expensive and service is variable, from professional to downright fraudulent. And that variability can be truly unpredictable abroad.The beauty of UBER stock is that the underlying business consolidates riders and drivers under a mutually beneficial relationship: if either party acts up, that could spell a loss of convenience or income. * 7 Sin Stocks Whose Profits Are Too Irresistible to Pass Up Further, the Pew Research Center indicates that a sizable number of Americans are trying ride-sharing platforms. Given that Uber has the largest footprint in the space, I believe Uber stock is an easy pick among stocks to buy. Fiverr International (FVRR)Source: Temitiman / Shutterstock.com I'd like to give a shout out to my fellow InvestorPlace colleague Laura Hoy for turning me on to Fiverr.One of the direct plays toward the gig economy, FVRR stock is a somewhat speculative idea. However, if you're building a portfolio of stocks to buy for the long haul, my reservations for the underlying company fade quickly.Prior to the surge of independent gig workers, many professionals sought the assistance of traditional employment agencies such as Robert Half International (NYSE:RHI). Here, the concept focused on large, networked organizations marketing talent to their client corporations. If a match was found, the talent would typically find themselves working as a full-time employee.But that model is becoming less relevant today. Instead, we have Fiverr, which connects gig workers to businesses that require work completed via short-term contracts.Over time, I see Fiverr working out its kinks — such as exposure to too many low-quality jobs. In the meantime, I think a long-term speculative bet on FVRR stock is warranted given where our society is headed. Square (SQ)Source: Jonathan Weiss / Shutterstock.com If you've followed my work for some time, you'll know that I'm generally very bullish on Square. Therefore, when I witnessed the sizable hit to SQ stock due to coronavirus fears, I was not alarmed.I'll go a step further. Because Square appears technically vulnerable, shares are liable to fall more. Even so, put Square on your list of stocks to buy for your 10-year old.Most people are familiar with Square due to its now-ubiquitous payment processors. Right here, the company demonstrated its true intent: to disrupt the payments space and level the playing field for small businesses.With their innovations, entrepreneurs received a viable alternative to inking a less-than-favorable contract with a traditional payment-services provider. * 7 Growth Stocks to Ride for the Rest of 2020 But the driving force behind SQ stock is its development of a small-business ecosystem. It's not a stretch to say that most entrepreneurs hate the day-to-day administrative BS: they'd rather focus on the fundamentals that make their business distinctive. Thanks to Square's intuitive ecosystem, small-business owners can do exactly that. PayPal (PYPL)Source: JHVEPhoto / Shutterstock.com I've spoken glowingly about digital payments processor PayPal. Primarily, I've been impressed with the blistering growth rate of its active users.It's making a fool out of the law of large numbers. However, no one should be surprised: PayPal is incredibly convenient and is aligned perfectly with the burgeoning gig economy, bolstering the case for PYPL stock.Over the next decade, I view PayPal as a no-brainer opportunity among tech-related stocks to buy. Yes, the market panic has severely hurt shares and more pain could follow. But no viral outbreak can unseat the progress that the underlying company has made. Unless, of course, you believe that we'll move back to analog payments!Another important factor to consider regarding PYPL stock is PayPal's push to help bank the unbanked.Due to social dynamics, not everyone can participate in the digital economy because of lack of access to the financial system. PayPal is actively bridging this gap, which gives it an ethical angle for those interested in positive social impacts. H&R Block (HRB)Source: Ken Wolter / Shutterstock.com Even before the coronavirus outbreak wrecked the early positive start in the markets, tax preparer H&R Block never was a favorite among investors.Easily, it's one of the choppiest names you'll encounter among New York Stock Exchange-traded equities. However, with changes to our taxes along with a shift in working culture, HRB stock may surprise down the line.For starters, President Donald Trump administration's tax code change wasn't popular with many employees who felt cheated on their refunds. As a result, it's conceivable that in the future, a liberal or progressive administration will try to make things right. If I know anything about the government, whoever's in charge will probably screw it up. * 8 5G Stocks to Get Rich Off Our Information Addiction But the more important catalyst for HRB stock is the gig economy. With many Americans making the shift from W-2 employees to 1099 workers, they will incur significant tax reporting changes. For 1099 rookies, it may be an overwhelming transition. However, H&R Block is here to help, so speculators shouldn't ignore it when it comes to considering stocks to buy. Splunk (SPLK)Source: Michael Vi / Shutterstock.com As we dive deeper into the information age, the commodity that is most important isn't necessarily physical but digital. I'm referring to data.Every day, we transmit data through the internet. Further, companies pay big money for it as it holds the key to our consumption behaviors. But making sense of all this data is a difficult task. And that's where Splunk comes in.While most tech firms talk about big data, Splunk consolidates vast and seemingly disparate information into actionable advice. Called the Data-to-Everything Platform, this powerful system allows Splunk's clients to make well-informed decisions. Further, the platform facilitates real-time data acquisition, giving clients tactical capabilities. Essentially, SPLK stock runs on harnessing the potential of the digital age.Earlier, though, I felt that SPLK stock was running a little too hot. Clearly, I was wrong when shares spiked in November of last year. However, due to the broader panic, Splunk has lost some of its momentum. This is giving investors a chance to buy on the dip. American Outdoor Brands (AOBC)Source: Shutterstock According to Pew, America is becoming more diverse and a majority of us believe that this is a positive development.Furthermore, Pew reports that only a very small, single-digit minority view diversity as a negative. However, I think this latter statistic is misleading because very few admit to their prejudices.Further, we inherently know that differences — though culturally enriching — also tend to breed tension and distrust. If you don't believe this, open your eyes to the attacks against Asian Americans due to ignorant coronavirus panic. Moreover, sociological studies have demonstrated that human differences are among the catalysts for armed conflicts. That being the case, it's time to take a long look at American Outdoor Brands. * 10 SPAC IPO Stocks to Buy as They Grow in Popularity I think the time has come for us to have a real discussion about firearms in America. The sad reality is that we have a sickness in this country. And yes, the deranged have access to weapons. But gun control will disproportionately affect law-abiding citizens who wish only to protect themselves and their families.The cat's out of the bag. America will probably be a much more divided and violent country in the future, which is why AOBC stock will cynically thrive over the long haul. Teva Pharmaceutical (TEVA)Source: JHVEPhoto / Shutterstock.com Out of the stocks to buy on this list, Teva Pharmaceutical has endured the most difficult journey over the last five years. For starters, the healthcare system is essentially broken. Families are paying exorbitant costs while often receiving less-than-ideal care. For TEVA stock specifically, the underlying company has found itself embroiled in multiple controversies, including price gouging.However, TEVA stock is off to a brilliant start in 2020, gaining over 34%. In fact, while the major indices printed red ink, Teva has steadily moved forward. Logically, some of the bullishness is based on the idea that the company is relatively insulated from the coronavirus outbreak. No matter what, demand for pharmaceuticals will always be strong.And this segues into another point. Admittedly, TEVA stock is optically one of the less favorable stocks to buy right now. Over time, however, most folks will realize that the organization is a necessary evil. Our broken healthcare system will not fix itself anytime soon. But in the interim, we need access to affordable generics. Like it or not, that's Teva's forte. Disney (DIS)Source: Ivan Marc / Shutterstock.com Disney stock slipped on the broader implications of the coronavirus epidemic. But also, longtime Disney CEO Bob Iger stepped down from the top role. For someone who has frequently pushed back retirement, Iger's move was a surprise. and it may have come too soon — as coronavirus continues to afflict the company, Iger has actually put his retirement on hold once more.But the way I see it, Disney owns the trifecta in entertainment. First, through incredibly viable acquisitions like the Star Wars franchise, they dominate the summer blockbuster narrative. Second, through their resorts and theme parks, Disney levers an enviable physical footprint. Third, the company has made huge strides in streaming with Disney+.Therefore, unless you think entertainment will go out of style, you can confidently bet on DIS stock.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 8 of the Best Stocks to Buy for ESG Investors * 3 Top Stocks You Should Watch to Invest Like Berkshire Hathaway * 3 India ETFs to Buy Now While No One Is Looking The post 10 Stocks to Buy for Your 10-Year-Old appeared first on InvestorPlace.

    from Yahoo Finance https://ift.tt/2XKe2dI

  • Cash rate on hold until after 2022? Buy these ASX dividend shares

    Interest rates

    Interest ratesInterest rates

    According to the latest weekly economic update by Westpac Banking Corp (ASX: WBC), its team continue to believe the cash rate will remain on hold at the record low of 0.25% beyond 2022.

    While this is great news for borrowers who will be able to benefit from low rates for some time to come, it is quite the opposite for income investors.

    The good news is that there are plenty of dividend shares out there that offer generous dividend yields.

    Two that I think would be great options for income investors are listed below. Here’s why I would buy them:

    Rural Funds Group (ASX: RFF)

    The first ASX dividend share to consider buying is Rural Funds. It is a leading agriculture-focused property company which owns a collection of high quality assets. These assets are leased to some of the biggest names in the industry such as Treasury Wine Estates Ltd (ASX: TWE). I’m a big fan of Rural Funds because of its long leases and the periodic rental increase included in them. This gives the company great visibility with its future earnings and ultimately its distributions. In FY 2021 it intends to grow its distribution by 4% to 11.28 cents per share. Based on the current Rural Funds share price, this equates to a very attractive 5.4% yield.

    Telstra Corporation Ltd (ASX: TLS)

    A second ASX dividend share to consider buying is Telstra. Times have been hard for the telco giant in recent years, but things are finally starting to improve. Due to its T22 strategy and the easing of the NBN headwind, I believe a return to growth is not far away. In the meantime, I’m confident that Telstra’s free cash flows will be sufficient to maintain its 16 cents per share fully franked dividend for the foreseeable future. This equates to a generous 4.75% dividend yield based on the latest Telstra share price. Though, it is worth noting that Telstra is due to release its full year results next week. So it may be prudent to wait for those before investing.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro owns shares of Westpac Banking. The Motley Fool Australia owns shares of and has recommended RURALFUNDS STAPLED and Telstra Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Cash rate on hold until after 2022? Buy these ASX dividend shares appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3inZZCu

  • 3 top ASX growth shares you should never sell

    Young male investor with a pink piggy bank and pile of gold coins

    Young male investor with a pink piggy bank and pile of gold coinsYoung male investor with a pink piggy bank and pile of gold coins

    I think there are some top ASX growth shares that you should never sell.

    There are some businesses that have long-term growth potential and are likely to be integral parts of our society for a very long time.

    When you hold a quality business that offers important products or services then they’re more likely to deliver solid returns over the long-term. 

    Here are three ideas:

    Growth share 1: CSL Limited (ASX: CSL)

    CSL is Australia’s biggest business, but I believe it still has plenty of growth potential for years to come.

    If you don’t know what CSL does, it’s a biotech company that develops biotherapies and influenza vaccines. Its products are used around the world to treat immunodeficiencies, bleeding disorders, hereditary angioedema, alpha 1 antitrypsin deficiency and neurological disorders. It’s one of the biggest plasma collection businesses. These services are going to be important for a very long time – human biology isn’t likely to change much over time. The ASX growth share could continue to develop new treatments to diversify its earnings – it invests heavily in research and development.

    At the moment it’s also involved in trying to find a healthcare treatment for COVID-19.

    After many years of strong growth, CSL is predicting that FY20 profit will be between US$2.11 billion to US$2.17 billion – this would be growth of 10% to 13% compared to FY19. The company could continue to generate decent compound growth of its profit over the long-term, meaning the shareholder returns should also be pretty good for the long-term too.

    It’s trading at 34x FY22’s estimated earnings at the current CSL share price.

    Growth share 2: Altium Limited (ASX: ALU)

    Altium is one of the most promising ASX growth shares in my opinion. It’s an electronic PCB software business that helps engineers design the items, devices and vehicles of the future.

    The software business has quite sticky revenue. It would take a large amount of training to change to another software business. As long as Altium keeps giving its clients a good, regularly-updated product then I think it has a good chance of achieving its goal of becoming the clear global leader in its industry. It’s aiming for 100,000 Altium Designer subscribers by 2025. This will help it achieve US$500 million revenue by 2025. 

    Its client base features many of the world’s most important technology businesses. Altium has effectively embedded itself into our society by providing its services to clients. Some of its most recognisable clients are: Amazon, Apple, Disney, Google, Boeing, Lockheed Martin, Tesla, Space X, NASA, Microsoft, Bosch, Honeywell and Fitbit.

    The ASX growth share has plenty of attributes you’d want from a business. It’s debt free. It has a growing cash balance, it has a growing profit margin and Altium is increasing its market share. Altium has aligned and focused management. It has a global revenue base. It’s regularly growing its dividend.

    Altium is an important business for helping the world’s development of new technology. At the current Altium share price it’s trading at 50x FY22’s estimated earnings and I think it could be a solid growth company over the next decade.

    Growth share 3: A2 Milk Company Ltd (ASX: A2M)

    A2 Milk has been a great ASX growth share over the past five years. I think that could continue as the business is steadily building its market share in China. It’s rapidly increasing its distribution footprint in the US. 

    The infant formula and other dairy products that A2 Milk sells is important. We all need nutrition.

    I think A2 Milk offers an attractive combination of defensive earnings and growth. For me, one of the most exciting aspects about A2 Milk is how many more countries that the company can expand into – it has a very long growth runway for this reason. It will soon be generating earnings in Canada after a licensing agreement with Agrifoods.

    The ASX growth share has no debt and a large cash balance which could be used for shareholder returns or acquisitions.

    At the current A2 Milk share price it’s trading at 29x FY22’s estimated earnings.

    Foolish takeaway

    I think each of these ASX growth shares have great long-term growth potential. I think A2 Milk could produce the strongest returns over the next five years as it’s priced the cheapest and has a lot of regions it can still grow in. I’d buy A2 Milk first for my portfolio. 

    These 3 stocks could be the next big movers in 2020

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

    *Returns as of 6/8/2020

    More reading

    Tristan Harrison owns shares of Altium. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Altium. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 top ASX growth shares you should never sell appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2XJqAlD

  • Airlines unlikely to recover until 2024, expert warns

    Airlines unlikely to recover until 2024, expert warnsSenior Analyst at Aviation Data Specialist OAG John Grant joins joins Yahoo Finance’s Zack Guzman to discuss the airline industry as CNBC reports that Delta is asking flight attendants to take unpaid leave amid COVID-19.

    from Yahoo Finance https://ift.tt/3gGndmT

  • Horizon Therapeutics Public Limited Company’s (NASDAQ:HZNP) Business Is Trailing The Market But Its Shares Aren’t

    Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) Business Is Trailing The Market But Its Shares Aren'tHorizon Therapeutics Public Limited Company's (NASDAQ:HZNP) price-to-earnings (or "P/E") ratio of 27.8x might make it…

    from Yahoo Finance https://ift.tt/3fDIw7h

  • The Next Bull Run Will Be Harder For Sorrento Therapeutics

    The Next Bull Run Will Be Harder For Sorrento TherapeuticsCNBC's Jim Cramer recently discussed some of the "clueless buying" that's been taking place in the markets. In particular, the Mad Money host is confounded about the Aug. 4 buying in Sorrento Therapeutics (NASDAQ:SRNE) stock.Source: Shutterstock The longtime investment guru recommended SRNE stock several weeks ago when it was trading at $8. InvestorPlace – Stock Market News, Stock Advice & Trading TipsInterestingly, while Cramer's bullish about the company's prospects due to its 30-minute spit test for the novel coronavirus, he has a hard time understanding why Sorrento's stock was up 30% a week after Sorrento's announcement. "Turns out the market was just stupid because today, on the exact same news … Sorrento rallied 31% to just under $13. The stock market's supposed to be efficient, but somehow it took Wall Street six days to process this news," Cramer stated. * 7 Travel Stocks to Buy Banking On Pent-Up DemandHe's kind of right. Sorrento Drops the Saliva NewsOn July 29, Sorrento issued a news release announcing it was entering into a licensing agreement with Columbia University for the rights to a rapid, one-step diagnostic test that detects SARS-CoV-2 virus from a saliva sample in 30 minutes."Unlike other commercially available diagnostic products, the test developed by Columbia's team, to be marketed by Sorrento under the COVI-TRACE™ name, holds all of the testing materials in a single tube and requires no specialized laboratory equipment, making it easily deployable for point of care, on-site or potentially at-home testing."That was a Wednesday. There were three days of trading between the announcement date and Aug. 4, the day its share price jumped by a third. If you include the weekend, that's almost six days. So, close enough.But it is weird, that at a time when the words Covid-19 have been said far more often than the number of U.S. cases, no one in the investment community took notice of something that could be vital to resuming normal activities in this country. Is SRNE Stock All That and a Bag of Chips?Cramer was ahead of the curve when it comes to the San Diego-based clinical-stage, antibody-centric, biopharmaceutical company. The question is whether he's right or not. If he is, SRNE's current price of $13.61 is certainly not expensive based on future revenue potential. On the other hand, its stock has almost doubled in two weeks. It's now valued at 64x sales. That's a lot for a company that only had $16.7 million in sales and a $90.9 million loss through the first six months of 2020.Late to the Sorrento party, I'll lean on my InvestorPlace colleague, Josh Enomoto, who once worked for the company and lives in San Diego, to get a better feel for whether Cramer is barking up the wrong tree. Josh's most recent discussion about the company also happens to have occurred on Aug. 4, the same day as Cramer's comments.In his commentary, he points out that if the claims by the Columbia University Medical Center team and Sorrento are found to be accurate – a true positive rate of 97% and a true negative rate of 100% – SRNE stock would skyrocket. My words, not his. However, and this is something that bears repeating from time to time when dealing with development-stage biopharmaceutical companies: Claims aren't the same thing as proven capabilities.Not to mention, there are massive drug companies out there who spend billions on research and development to create new drugs. Sure, in recent years, Big Pharma has acquired its way to growth, but the pendulum seems to be swinging back in the direction of organically derived medicine. "Bear in mind that the leaders in the diagnostic space are Abbott Laboratories (NYSE:ABT) and Roche Holding (OTCMKTS:RHHBY). As I just mentioned, Abbott has fielded many questions about its testing accuracy," Enomoto wrote."It's hard to believe that Sorrento won't at least face some setbacks when rigorous testing, including peer review and broadening the test sample size, are incorporated."My colleague is trying to point out that Sorrento is pivoting from being an oncology-focused firm to one solving the problems of the here and now. That's not an easy thing to do at the best of times. But when better-financed companies are stumbling to the finish line, the likelihood of Sorrento running the gauntlet free of setbacks does seem remote. The Bottom LineIn past articles about Covid-19 related vaccines, treatments, and tests, I've recommended investors interested in placing a bet on one or more of the winners, make a safer play, and buy shares of the ETFMG Treatments Testing and Advancements ETF (NYSEARCA:GERM).Unfortunately, for investors interested in SRNE stock, it's not one of the 56 holdings owned by the ETF, so you're out of luck on the safety play. I bet if you asked Cramer how he feels about buying at almost $14 a share, he'd be a lot less bullish than he was at $8. Like my colleague, I'm neither a bull nor a bear when it comes to Sorrento, but I do think the climb to $20 will be a lot more difficult than the climb from single digits. I wouldn't buy SRNE stock, but that doesn't mean you shouldn't. Will Ashworth has written about investments full-time since 2008. Publications where he's appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post The Next Bull Run Will Be Harder For Sorrento Therapeutics appeared first on InvestorPlace.

    from Yahoo Finance https://ift.tt/2XHMXYE

  • Top brokers name 3 ASX shares to buy next week

    sign containing the words buy now, asx growth shares

    sign containing the words buy now, asx growth sharessign containing the words buy now, asx growth shares

    Last week saw a large number of broker notes hitting the wires once again. Three buy ratings that caught my eye are summarised below.

    Here’s why brokers think investors ought to buy them next week:

    Corporate Travel Management Ltd (ASX: CTD)

    According to a note out of Morgans, its analysts have upgraded this corporate travel company’s shares to an add rating with a $12.85 price target. Morgans made the move partly on valuation grounds after a sizeable pullback in the Corporate Travel Management share price. It notes that this has left its shares trading at a big discount to its valuation. Another positive is its belief that corporate travel demand has been stronger than expected recently. This could mean it surprises to the upside in FY 2021. While I think Morgans makes some good points, I’m staying clear of the travel sector until the pandemic passes.

    CSL Limited (ASX: CSL)

    Analysts at UBS have retained their buy rating but cut the price target on this biotech giant’s shares to $320.00. According to the note, the broker has been looking at the performance of its competitors and notes positive results during the June quarter. And while the outlook on plasma collections remains tough, it is optimistic that other parts of the business will offset this weakness. As a result, it still expects earnings growth in FY 2021. I agree with UBS and would be a buyer of CSL’s shares.

    Qantas Airways Limited (ASX: QAN)

    Another note out of UBS reveals that its analysts have retained their buy rating and $4.60 price target on this airline operator’s shares. This follows the release of Virgin Australia’s business update last week. It sees the sweeping changes that Virgin Australia is making as a positive for Qantas and could lead to market share gains in the future. While I do think the Qantas share price is good value, there are too many uncertainties in the travel market right now to give me enough confidence to invest.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Corporate Travel Management Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Top brokers name 3 ASX shares to buy next week appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2DO9AU6

  • It Still Is Way Too Early to Consider Setting Sail With Carnival Stock

    It Still Is Way Too Early to Consider Setting Sail With Carnival StockMany stocks hammered by the novel coronavirus have bounced back, but not names like Carnival Cruise Lines (NYSE:CCL). Investors may be willing to take a gamble with airlines, but CCL stock just makes people nervous.Source: Ruth Peterkin / Shutterstock.com No surprises here. While airlines are slowly climbing back from their lows, cruise ships remain mothballed. With no-sail orders extended to Oct 31, cash burn is set to continue for Carnival, as well as for its rivals Royal Caribbean (NYSE:RCL), and Norwegian Cruise Line Holdings (NYSE:NCLH).So, what does this mean for the industry's largest operator? At first glance, you may think being size equals strength. Yet, as I wrote back in June, this may not be the strongest cruise stock out there.InvestorPlace – Stock Market News, Stock Advice & Trading TipsWhy? For starters, Royal Caribbean may be smaller, but it could recover much faster. Also, despite its size, Carnival may be behind its rivals in terms of liquidity and balance sheet strength. * 7 Travel Stocks to Buy Banking On Pent-Up Demand And, with the odds favoring a "return to normal" much further on the horizon for cruise lines compared to other hard-hit industries, why buy CCL stock, or any cruise name, now? As the situation continues to be tough, you may have the opportunity to enter a position at much lower prices.With this in mind, let's dive in and see why it's best to stay on the sidelines for now. Riding Out the Storm With CCL StockAs InvestorPlace's Mark Hake discussed Aug 4, no-sail orders may continue to be extended until there's a coronavirus vaccine. In other words, it probably won't be until early 2021 at the earliest that cruise lines can even think about "returning to normal."In the meantime, the heavy cash burn we've seen so far shall continue. And, how much is Carnival burning through each month? Previously, the company projected $650 million per month in cash burn through the second half of 2020.And, with ships not setting sail until at least November, that projection's probably not coming down. Sure, with over $10 billion in liquidity, the company can stay afloat for more than a year. But, tapping into this lifeline means Carnival's going to get out of this in a much weaker position.With a heavy debt load incurred during this rough environment, it's a long road ahead for shares to retrace prior levels. And, with uncertainty over how quickly cruise demand will bounce back, shares may head lower before it's all said and done. This Ship Could Sink FurtherIt's easy to compare cruise line stocks to airline stocks, but as our own Matt McCall wrote last month, there's a key difference. As he put it, there are multiple demand channels for air travel.Sure, like cruise lines, people hop on planes for personal vacations. However, there are situations where people have to fly. Whether its to attend a family member's wedding or required travel for business, there's more at play that can help get the airlines back on their feet.Cruise lines? All they have is the vacationer market. And, given there are plenty of vacation substitutes to cruise travel, this industry could still struggle. Even after ships set sail again.So, where does that leave Carnival? Post-pandemic, profitability may continue to be a challenge. Coupled with what will be a highly-levered balance sheet, and it's hard to see shares making any sort of epic comeback.In fact, shares could keep on sinking lower for now. While the worst-case scenario may already be priced into airline stocks, it's debatable whether that's the case with cruise stocks.How low could CCL stock go? That's hard to tell. The specter of a vaccine coming out by early next year may be giving shares some support. But, what happens if bringing a vaccine to market takes longer than expected? Shares could fall back to lows set during March's pandemic-driven sell-off.Granted, that may be a great entry point for a "bottom-fisher's buy." But, for now, the prospect of further decline means you ought to steer clear for now. Wait and See If CCL Stock Falls Back to Single DigitsAs the world contends with the coronavirus, there's still an opportunity to take high-risk, high-return positions in hard-hit stocks. But, compared to other struggling industries like airlines, cruise operators like Carnival face greater hurdles.Hemorrhaging cash while its ships sit mothballed, the situation could continue to deteriorate. That may mean a great entry point down the road (if shares fall back to single-digits).But, for now, take a "wait-and-see" approach with CCL stock. There's no compelling reason to climb aboard today.Thomas Niel, contributor to InvestorPlace, has written single-stock analysis since 2016. As of this writing, Thomas Niel did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post It Still Is Way Too Early to Consider Setting Sail With Carnival Stock appeared first on InvestorPlace.

    from Yahoo Finance https://ift.tt/2XHY7wO